# Comparative Study of Sitagliptin and Gliclazide With Metformin in Type 2 Diabetes Patients With Glucotoxicity

Study · id `cardio:ct-nct06613750` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06613750](<https://clinicaltrials.gov/study/NCT06613750>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06613750

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 129 participants.

## Technical summary

Registry record NCT06613750. Randomized; no masking; primary purpose treatment. Start 2024-06-01 (actual); primary completion 2024-06-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 129 participants (enrolled count; ClinicalTrials.gov record NCT06613750, source copy `cardio:ctgov-nct06613750-2024-09-26`, retrieved 2026-10-26)
- Started: 2024-06-01 (actual) (ClinicalTrials.gov record NCT06613750, source copy `cardio:ctgov-nct06613750-2024-09-26`, retrieved 2026-10-26)
- Primary completion: 2024-06-30 (actual) (ClinicalTrials.gov record NCT06613750, source copy `cardio:ctgov-nct06613750-2024-09-26`, retrieved 2026-10-26)
- Completion: 2024-07-01 (actual) (ClinicalTrials.gov record NCT06613750, source copy `cardio:ctgov-nct06613750-2024-09-26`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06613750, source copy `cardio:ctgov-nct06613750-2024-09-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06613750-2024-09-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparative Study of Sitagliptin and Gliclazide With Metformin in Type 2 Diabetes Patients With Glucotoxicity
- Acronym: SG Metformin
- Condition: Type 2 Diabetes Mellitus
- Condition: Glucotoxicity
- Intervention (Drug): Sitagliptin and Gliclazide
- Intervention (Drug): Metformin
- Lead sponsor: Zhibin Xu
- Lead sponsor class: OTHER
- Collaborator: Nanfang Hospital, Southern Medical University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as a collaborator: Nanfang Hospital, Southern Medical University (`cardio:org-nanfang-hospital-southern-medical-university`)

## Provenance

Content hash: da37182768f8c1cd133228e1daa05984c1bf2e4b7913164fad6d22a04a9d2c0a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
